Home » Stocks » KemPharm

KemPharm, Inc. (KMPH)

Stock Price: $0.480 USD 0.050 (11.63%)
Updated Aug 10, 2020 3:59 PM EDT - End of day
After-hours: $0.479 -0.001 (-0.21%) Aug 10, 4:02 PM

Stock Price Chart

Key Info

Market Cap 31.57M
Revenue (ttm) 14.93M
Net Income (ttm) -17.99M
Shares Out 65.76M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $0.480
Previous Close $0.430
Change ($) 0.050
Change (%) 11.63%
Day's Open 0.220
Day's Range 0.420 - 0.500
Day's Volume 2,178,881
52-Week Range 0.121 - 1.370

More Stats

Market Cap 31.57M
Enterprise Value 99.77M
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 65.76M
Float 56.83M
EPS (basic) -0.54
EPS (diluted) -0.51
FCF / Share -0.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 635,833
Short Ratio 0.41
Short % of Float 1.14%
Beta 1.83
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.11
PB Ratio n/a
Revenue 14.93M
Operating Income -12.74M
Net Income -17.99M
Free Cash Flow -14.71M
Net Cash -68.20M
Net Cash / Share -1.04
Gross Margin 66.28%
Operating Margin -85.36%
Profit Margin -120.50%
FCF Margin -98.56%
ROA -51.79%
ROE n/a
ROIC -22.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $0.480
Target: 1.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit12.84------
Operating Income-20.34-55.90-33.37-37.48-22.81-16.44-4.72
Net Income-24.52-56.47-43.39-16.52-54.66-24.46-5.23
Shares Outstanding29.6517.9314.6514.607.372.382.38
Earnings Per Share-0.83-3.15-2.96-1.13-7.42-10.27-2.20
Operating Cash Flow-23.74-54.20-33.10-29.77-20.27-14.67-4.33
Capital Expenditures-0.03-0.02-0.18-0.64-0.14-0.05-0.03
Free Cash Flow-23.76-54.22-33.28-30.42-20.40-14.72-4.36
Cash & Equivalents3.5622.3843.3368.8751.3210.260.00
Total Debt79.5382.0593.4891.9821.9718.95-
Net Cash / Debt-75.97-59.67-50.15-23.1229.35-8.700.00
Book Value-74.46-66.57-57.52-18.70-10.12-48.51-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name KemPharm, Inc.
Country United States
Employees 22
CEO Travis C. Mickle

Stock Information

Ticker Symbol KMPH
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: KMPH
IPO Date April 16, 2015


KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. It also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. The company has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. KemPharm, Inc. was founded in 2006 and is headquartered in Celebration, Florida.